<DOC>
	<DOCNO>NCT00346606</DOCNO>
	<brief_summary>Objective : To compare efficacy desloratadine 5mg ( Denosin® ) levocetirizine 5mg ( Xyzal® ) daily treatment patient CIU 6 week . Trial design : Randomized , Double-Blind , Active-Controlled , Parallel-Group Study . Primary end point : To evaluate change average AM/PM reflective pruritus score baseline record subject ’ diary first two week treatment . Secondary Objectives : To assess efficacy safety desloratadine 5mg ( Denosin® ) levocetirizine 5mg ( Xyzal® ) daily treatment subject CIU 6 week .</brief_summary>
	<brief_title>The Efficacy Safety Desloratadine With Levocetirizine Treatment Chronic Idiopathic Urticaria</brief_title>
	<detailed_description>Objective : To compare efficacy desloratadine 5mg ( Denosin® ) levocetirizine 5mg ( Xyzal® ) daily treatment patient CIU 6 week . Trial design : Randomized , Double-Blind , Active-Controlled , Parallel-Group Study . Primary endpoint : To evaluate change average AM/PM reflective pruritus score baseline record subject ’ diary first two week treatment . Secondary Objectives : To assess efficacy safety desloratadine 5mg ( Denosin® ) levocetirizine 5mg ( Xyzal® ) daily treatment subject CIU 6 week . Primary endpoint : To evaluate change average AM/PM reflective pruritus score baseline record patient diary first two week treatment Secondary Endpoints- To evaluate change average AM/PM reflective pruritus score baseline record subject ’ diary 6 week . To evaluate reflective average AM/PM score number hive , size large hive , total symptom score ( sum pruritus , number hive , size large hive score ) . Average individual AM/PM instantaneous score pruritus , number hive , size large hive also evaluate . AM instantaneous score pruritus , number hive , size large hive also evaluate . PM instantaneous score pruritus , number hive , size large hive also evaluate . PM reflective score pruritus , number hive , size large hive also evaluate . The interference sleep ( AM reflective ) , interference daily activity ( PM reflective ) secondary efficacy outcome . Therapeutic response evaluate visit 3~5 . Safety evaluate include vital sign record visit , whereas sleep latency use Epworth Sleepiness Scale ( ESS ) questionnaire Visual analogue Scale ( VAS ) score visit 2~5 . Stanford Sleepiness Scale ( SSS ) score accord instruction diary card visit . All adverse event record graded severity visit 2~5 .</detailed_description>
	<mesh_term>Urticaria</mesh_term>
	<mesh_term>Desloratadine</mesh_term>
	<mesh_term>Levocetirizine</mesh_term>
	<mesh_term>Cetirizine</mesh_term>
	<criteria>The subject deputy read inform sign Informed Consent Agreement subject willing able participate study . The subject ≥ 12 year old . The subject document sign symptom CIU 6 week . The subject CIU flare 3 week screen , urticarial lesion visible 3 day per week . The overall severity CIU least mild moderate screening baseline , subject least mild moderate pruritus , hive apparent screening , subject intention treatment . The subject receive histamine , corticosteroid , ketotifene , systemic antibiotic , nedocromil , sodium cromoglycate thyroxin drug within 7 day precede randomization . The subject receive investigational drug within one month precede randomization . The subject previous nonresponse antihistamine . The subject previous allergy allergy desloratadine levocetirizine . The subject need longterm corticosteroid treatment ( include inhale , oral topical dosage ) . The subject autoimmune disease . The subject ’ urticaria physical urticaria , cholinergic urticaria angioedema . The subject situation pregnancy breastfeed . The subject liver dysfunction ( AST ≧ 3 time normal range ; ALT ≧ 3 time normal range ) renal dysfunction ( Creatinine ≧ 3.0mg/dl ) . The subject unable keep accurate diary disease symptom . The subject significant concomitant illness , , opinion investigator , interfere evaluation study medication .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2006</verification_date>
	<keyword>Chronic Idiopathic Urticaria</keyword>
	<keyword>Desloratadine</keyword>
	<keyword>Denosin</keyword>
	<keyword>Levocetirizine</keyword>
</DOC>